Abstract
Basal cell carcinoma (BCC) is the most common skin cancer. Metastatic BCC is rare (0,0028% to 0,5%), with a very poor prognosis, survival rates of 3 years, in cases of locoregional lymphatic metastases,is estimated at 8 months. For this form of basal cell carcinoma,treatment is based on surgery and radiotherapy, chemotherapy bye Platinum-based or the inhibitors of the Hedgehog vismodegibcan be used for non-operative patients. We report a case of a 41 years old male man who suffered from BCC on his right cheek with lymph node metastases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
